Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting

INTRODUCTION: Type 2 diabetes represents a continuing healthcare challenge, and choosing cost-effective treatments is crucial to ensure that healthcare resources are used efficiently. The present analysis assessed the cost-effectiveness of once-weekly semaglutide 1 mg versus empagliflozin 25 mg for...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Ther
Autors principals: Capehorn, Matthew, Hallén, Nino, Baker-Knight, James, Glah, Divina, Hunt, Barnaby
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7846640/
https://ncbi.nlm.nih.gov/pubmed/33423240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-020-00989-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars